Hormonal
Long-acting GLP-1 receptor agonists provide superior glycemic control (HbA1c) compared to short-acting GLP-1 receptor agonists, though short-acting agents may offer greater weight loss benefits.
If your main goal is lowering your average blood sugar (HbA1c), choose a long-acting GLP-1 agonist (like dulaglutide or liraglutide). If weight loss is your primary driver, short-acting options (like exenatide) might offer a slight edge, though long-acting agents are still effective for weight.
Long-acting GLP-1 RAs were better than short-acting ones in reducing HbA1c and fasting glucose, but similar regarding body weight... Short-acting GLP-1 receptor agonists had a similar effect on HbA1c concentrations compared to insulin treatment... while long-acting GLP-1 RAs caused a significantly greater reduction than insulin treatment
Why this rating
Meta-analysis of 19 trials with subgroup analysis.
Source
A meta‐analysis comparing clinical effects of short‐ or long‐acting <scp>GLP</scp> ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al. · Diabetes Obesity and Metabolism · 2016
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →